Supplementary appendix
|
|
- Alexis Bennett
- 6 years ago
- Views:
Transcription
1 Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol 2014; published online June 10.
2 Augmented post-remission therapy for detectable minimal residual disease in children and young people with clinical standard and intermediate risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Ajay Vora, Nick Goulden, Chris Mitchell, Jeremy Hancock, Rachael Hough, Clare Rowntree, Anthony V Moorman, and Rachel Wade. Pages 2 7: Supplementary Tables APPENDIX Contents Table 1 : Details of 3 treatment regimens in UKALL 2003 Table 2: Cumulative doses of drugs in Regimens A, B and C with 2 delayed intensification courses Table 3 : Number of patients with dose reductions below 90% of protocol doses by regimen. Table 4 : Participating centres and principal investigators Page 8 : Supplementary Figures 1a Event-free survival in the trial overall 1b Event free survival and Relapse Rate in MRD low risk randomisation arms 1
3 Supplementary table 1. Details of 3 treatment regimens in UKALL 2003 Induction Consolidation Interim maintenance 1 Delayed intensification 1 Interim maintenance 2 Delayed intensification 2 Continuing therapy Clinical Standard Risk VCR 1.5 mg/m 2 i.v. on days 2, 9, 16 and 23 Dexamethasone 6.mg/m 2 p.o. on days units/m2 days 4 and 18 IT MTX 1 on days 1 & 8. If > 25% blasts in day 15 BM: Daunorubicin 45 mg/m 2 i.v. on days 16 and 23, if switched to HR from day 15 Steroids: Taper steroids over 7 days to zero, days 2-8 VCR 1.5 mg/m 2 i.v. on day 2 (week 5) 75 mg/m 2 p.o.. daily on days 2 29 (weeks 5 8) IT MTX 1 on days 1, 8, 15 and 22 Steroid as randomized for days 1-5 and VCR 1.5 mg/m 2 i.v. on days 1 and mg/m 2 p.o.. daily Methotrexate 20 mg/m 2 p.o. weekly on days 1, 8, 15, 22, 36, 43 and 50 Dexamethasone 10mg/m 2 p.o. on days 2-8 and VCR 1.5 mg/m 2 i.v. on days 2, 9 and 16 Doxorubicin 25 mg/m 2 i.v. on days 2, 9, units/m2 on day 4 Cyclophosphamide 1 g/m 2 i.v. on day mg/m 2 p.o.. daily. on days Cytarabine 75 mg/m 2 i.v. or s.c. on days and IT MTX 1 on days 1, 29 and 36 Dexamethasone 6.mg/m 2 p.o days 1-5 and VCR 1.5 mg/m 2 on days 1 and mg/m 2 p.o.. daily Methotrexate 20 mg/m 2 p.o. weekly on days 1, 8, 15, 22, 29, 36, 43 and 50 Dexamethasone 10 mg/m 2 p.o. on days 2-8 and VCR 1.5 mg/m 2 i.v. on days 2, 9 and 16 Doxorubicin 25 mg/m 2 i.v. on days 2, 9 and units/m2 on day 4 Cyclophosphamide 1 g/m 2 i.v. on day mg/m 2 p.o.. daily. on days Cytarabine 75 mg/m 2 i.v. or s.c. on days and IT MTX 1 on days 1, 29 and week cycles consisting of: Dexamethasone 6.mg/m 2 p.o on days 1-5, and VCR 1.5 mg/m 2 i.v. on days 1, 29 and mg/m 2 p.o.. daily Methotrexate 20 mg/m 2 p.o. weekly on days 1, 8, 22, 29, 36, 43, 50, 57, 64, 71 and 78 IT MTX 1 on day 15 Weeks 1-4 Weeks 5-8 Weeks 9-16 Weeks Weeks Weeks Weeks (girls) Weeks (boys) Clinical Intermediate risk Taper steroids.over 7 days. Same as standard risk Same as standard risk Same as standard risk Same as standard risk Same as standard risk As for standard risk plus Daunorubicin 25 mg/m 2 i.v. on days 2, 9, 16, and 23. Day 8 BM > 25% blasts change to high risk protocol at week 5. Cyclophosphamide 1g/m 2 i.v. on days 1 and 15 Cytarabine 75 mg/m 2 i.v. days 2-5, 9-12, 16-19, mg/m 2 p.o. on days 1-28 IT MTX 1 on days 1, 8, 15 and 22 Weeks 1-4 Weeks 5-9 Weeks Weeks Weeks Weeks Weeks (girls) Weeks (boys) 2
4 Supplementary table 1 continued Induction Consolidation Interim maintenance 1 Delayed intensification 1 Interim maintenance 2 Delayed intensification 2 Continuing therapy Clinical High Risk and MRD High Risk by randomized allocation Induction as for intermediate risk or as described above for standard risk with > 25% blasts in day 15 BM Steroids: Taper steroids over 7 days Augmented BFM consolidation Cyclophosphamide 1 g/m 2 i.v. on days 1 and 29 Cytarabine 75 mg/m 2 i.v. on days 2 5, 9 12, and mg/m 2 p.o. on days 1 14 and VCR 1.5 mg/m 2 i.v. on days 16, 23, 44 and iu/m 2 on days 16 and 44 Intrathecal therapy IT MTX 1 on days 1, 8, 15 and 22, Capizzi I VCR 1.5 mg/m 2 i.v. on days 2, 12, 22, 32 and 42 Methotrexate starting on day 2 at 100 mg/m 2 i.v. and increasing by 50 mg/m 2 every 10 days as permitted by toxicity 1000 iu/m 2 days 3 and 23 Intrathecal therapy IT MTX 1 on days 1 and 31 As for standard risk but with additional doses of vincristine 1.5 mg/m 2 i.v. on days 43 and 50 and PEG asparaginase 1000 iu/m 2 on days 5 and 43 Capizzi II VCR 1.5 mg/m 2 i.v. on days 2, 12, 22, 32 and 42 Methotrexate starting on day 2 at a dose 50 mg/m 2 i.v. below the dose attained in Capizzi I and increasing by 50 mg/m 2 every 10 days as permitted by toxicity 1000 iu/m 2 days 3 and 23 Intrathecal therapy IT MTX 1 on days 1 and 31 As for standard risk but with additional doses of vincristine 1.5 mg/m 2 i.v. on days 43 and 50 and PEG asparaginase 1000 iu/m 2 days 5 and 43 Same as standard risk Weeks 1-4 Weeks 5-13 Weeks Weeks Weeks Weeks Weeks (girls) Weeks (boys0 1 IT MTX dose <2yrs: 8mg; 2yrs: 10mg; 3+yrs: 12mg CNS, central nervous system; CT, continuing therapy; VCR, vincristine;;, Oncospar (Medac GmBH)IT MTX; intrathecal methotrexate; HD MTX, high dose intravenous methotrexate; p.o., oral; i.v., intravenous; s.c., sub-cutaneous; i.m., intramuscular 3
5 Supplementary Table 2 Cumulative doses of drugs in Regimens A, B and C with 2 delayed intensification courses Agents (mg/m 2 ) VCR DEX PEG ASP DNR/ DOX CYCLO ARA-C IV MTX REGIMEN A GIRLS BOYS REGIMEN B GIRLS BOYS REGIMEN C GIRLS BOYS (maximum) 4
6 Supplementary Table 3 Number of patients with dose reductions below 90% of protocol doses by regimen. Treatment regimen given <90% dose postinduction? A B C Total No Yes Total Only 5 patients crossed-over from regimen C to standard regimen due to toxicity (1 = prolonged neutropenia, 1 = neurotoxicity, 2 = Capizzi MTX related mucositis, 1 = other toxicity (no further info provided). 5
7 Supplementary Table 4: UKALL Participating centres and principal investigators Site Principal Investigator Number of eligible patients recruited Great Ormond Street Hospital Dr P Ancliff 286 Birmingham Children's Hospital Dr M Velangi 273 Our Lady's Hospital for Sick Children, Ireland Prof O Smith 250 Royal Marsden Hospital Dr D Lancaster 245 Addenbrooke's NHS Trust Dr M Gattens 186 Bristol Royal Hospital for Children / Bristol Haematology and Oncology Dr M Cummins 172 Royal Manchester Children's Hospital Dr J Grainger 159 Oxford Radcliffe Hospitals Dr G Hall 155 Alder Hey Children's Hospital Dr M Caswell 139 Southampton University Hospital Trust Dr M Morgan 137 St. James's University Hospital / Leeds General Infirmary Dr S Kinsey 142 Yorkhill NHS Trust Prof B Gibson 126 Royal Victoria Infirmary Dr S Bailey 121 University Hospital of Wales / Llandough Hospital NHS Trust Dr M Jenney 109 Sheffield Children's Hospital Prof A Vora 91 Nottingham University Hospital / Nottingham City Hospital Dr S Stokley 96 University College Hospital Dr S Daw 86 Royal Hospital for Sick Children, Edinburgh Dr A Thomas 79 Royal Belfast Hospital Dr C Macartney 75 Leicester Royal Infirmary Dr M Madi 68 Royal Aberdeen Children's Hospital / Aberdeen Royal Infirmary Dr D King 25 Christie Hospitals NHS Trust Dr A Bloor 16 Northampton General Hospital Dr B Koodiyedath 14 Royal Hallamshire Hospital Dr N Morley 7 Queen Elizabeth Hospital Dr S Chaganti 7 University Hospital of North Staffs Dr D Chandra 6 Beatson West of Scotland Cancer Centre Dr M Drummond 6 6
8 Heart of England NHS Foundation Prof D Milligan 5 Victoria Hospital, Scotland Dr S Rogers 5 Taunton & Somerset NHS Trust Dr S Bolam 4 St. Bartholomew's Hospital Dr M Smith 4 Guy's Hospital Dr R Carr 4 Western General Hospital Dr P Roddie 4 Belfast City Hospital Dr R Cuthbert 4 Royal Devon and Exeter Hospital Dr M Hamilton 3 Royal Free Hospital Dr A Fielding 4 James Cook University Hospital Dr D Plews 2 Manchester Royal Infirmary Prof J Yin 2 Poole Hospital NHS Trust Dr F Jack 2 University Hospital Coventry Dr O Chapman 1 Norfolk & Norwich University Hospital Dr J Wimperis 1 Wycombe General Hospital Dr A O Hea 1 Royal Bournemouth Hospital Dr J Chacko 1 Salisbury NHS Foundation Trust Dr J Cullis 1 Monklands District General Hospital Dr J Murphy 1 Mercy University Hospital, Ireland Dr M Madden 1 7
9 Supplementary Figures 1a 1b 8
The Birmingham Institute of Translational Medicine. Professor Charles Craddock
The Birmingham Institute of Translational Medicine Professor Charles Craddock Challenges in delivering on a translational medicine agenda After decades of investment in basic research it is now apparent
More informationPhase 1 Trial of CXD101 in Patients With Advanced Cancer
Trial Summary There are currently 28 trials Phase 1 Trial of CXD101 in Patients With Advanced Cancer Treatment: CXD101 Myeloma stage: Relapsed, Refractory, Newly Diagnosed, High risk myeloma Trial phase:
More informationImmunoglobulin Database Report 2015/16
Immunoglobulin Database Report 2015/16 1 Database Overview Rob Hollingsworth CHAPTER 1 Introduction I would firstly like to thank all Trusts and their staff that continue to support and provide data to
More informationAnnual Report 2016/17
Annual Report 2016/17 Compiled by Rob Hollingsworth, Mark Foster MDSAS 1 Database CHAPTER 1 Overview Rob Hollingsworth Introduction As is the case each year, I would firstly like to thank all Trusts and
More informationDFCI IRB ADVERSE EVENT REPORTING FORM
Office for Human Research Studies DANA-FARBER / HARVARD CANCER CENTER DFCI Protocol No.: 06-254 OHRS USE ONLY HRC: AE #: (unless submitted with an Amendment) Related AM #: DFCI IRB ADVERSE EVENT REPORTING
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationDr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationTRANSLATIONAL RESEARCH PARTNERSHIPS
TRANSLATIONAL RESEARCH PARTNERSHIPS Introduction The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. NIHR Translational Research
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationType of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis.
Coagulation disorders induced by L-asparaginase: correction with and without fresh-frozen plasma Glasmacher A, Kleinschmidt R, Unkrig C, Mezger J, Scharf R E Record Status This is a critical abstract of
More informationImmunochemistry in Clinical Laboratory Medicine
Immunochemistry in Clinical Laboratory Medicine 1m munochem istry in eli n i c a I Lab 0 rat 0 ry Medicine Edited by A. Milford Ward and J. T. Whicher Proceedings of a symposium held at the University
More informationNIHR at 10: Wessex. Professor Chris Whitty Chief Scientific Adviser Department of Health
NIHR at 10: Wessex Professor Chris Whitty Chief Scientific Adviser Department of Health Building on 10 remarkable years The extraordinary advances in health are based on evidence and science, properly
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Carfilzomib (Kyprolis) for Multiple Myeloma March 30, 2017
pan-canadian Oncology Drug Review Final Economic Guidance Report Carfilzomib (Kyprolis) for Multiple Myeloma March 30, 2017 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationIncreasing Competitiveness in Clinical Research. November 2011
Increasing Competitiveness in Clinical Research November 2011 Introduction The UK is witnessing a transformation in the number and qualityof clinical trials conducted in the country. This transformation
More informationImmunoglobulin Database Report 2014/15
Immunoglobulin Database Report 2014/15 1 Database Overview Rob Hollingsworth CHAPTER 1 Introduction Firstly, thanks to all Trusts that continue to provide data to the National Immunoglobulin Database.
More informationEducation and Training Committee 8 September Education and Training Panel decisions May 2011 to present
Education and Training Committee 8 September 2011 Education and Training Panel decisions May 2011 to present Executive summary and recommendations Introduction Meetings of the Education and Training Panels
More informationMyeloma XII (ACCoRd) Myeloma Infosheet Series. Clinical trials and novel drugs Infoline:
Myeloma XII (ACCoRd) This Infosheet provides information about what the Myeloma XII clinical trial is, why it is taking place and what is involved if patients decide to take part in the trial. This Infosheet
More informationManagement of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison
Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison Consultant Nephrologist, Hawke s Bay DHB, NZ Senior Lecturer, University of Birmingham, Birmingham, UK Why are nephrologists interested
More informationSalvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Arnon Nagler, M.D., M.Sc Director Hematology Division BMT and Cord Blood Bank Chair Israeli BMT Association Chaim Sheba Medical Center,
More informationPublished 07 February 2011 Page January 2011
filgrastim 12 million units (120microgram) / 0.2mL, 30 million units (300microgram) / 0.5mL, 48 million units (480microgram) / 0.5mL solution for injection/infusion in pre-filled syringe (Nivestim) SMC
More informationSupporting efficient and effective clinical research in the UK
Supporting efficient and effective clinical research in the UK National Institute for Health Research 10 years of delivering health and care research for the nation HRB CRCI Launch Dr Matthew Hallsworth
More informationPharmacogenomics and clinical relevance in diverse populations. Mary V. Relling, Pharm.D.
Pharmacogenomics and clinical relevance in diverse populations Mary V. Relling, Pharm.D. Many factors influence drug disposition & response but inherited genetic variation has an underlying effect Pharmacogenetics
More informationNational Horizon Scanning Centre. Cladribine (Movectro) for multiple sclerosis; relapsing-remitting. April 2008
Cladribine (Movectro) for multiple sclerosis; relapsing-remitting April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationTranslational development of Therapeutic Lymphoma Vaccines
Translational development of Therapeutic Lymphoma Vaccines Larry W. Kwak, M.D., Ph.D. Chairman, Department of Lymphoma/Myeloma Justin Distinguished Chair in Leukemia Research Assoc. Director, Center for
More informationGUIDELINES FOR THE DOSE BANDING OF CANCER CHEMOTHERAPY
GUIDELINES FOR THE DOSE BANDING OF CANCER CHEMOTHERAPY Quality and safety for every patient every time Document Control Prepared By Issue Date Approved By Review Date Version Contributors Comments/ Amendment
More information2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals
2111: ALL Post-HCT The Acute Lymphoblastic Leukemia Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific post-hct data such as: planned treatments post-hct, the
More informationNeutrophil count prediction for personalized drug dosing in childhood cancer patients receiving 6- mercaptopurine chemotherapy treatment
Neutrophil count prediction for personalized drug dosing in childhood cancer patients receiving 6- mercaptopurine chemotherapy treatment Dalila Avdic, Michael Gallimore, Mike J. W. Riley, Chris Bingham
More informationAgainst this background, the use of multiple doses, principally double, continues. The purpose of this audit was to:-
London Regional Transfusion Committee Audit of Multiple Dose Platelet Transfusion Requests across the London Regional Transfusion Committee region during a one week period in December 2014. Rachel Moss,
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Prof Gordon Cook Professor of Haematology and Myeloma Studies University of Leeds & Leeds Cancer Centre #MyelomaInfodays This talk will cover The
More information1 Final publishable summary report... 1
1 Final publishable summary report Content 1 Final publishable summary report... 1 1.1 Executive summary... 3 1.2 A summary description of project context and objectives... 5 1.3 A description of the main
More informationVenetoclax (Venclyxto )
Venetoclax (Venclyxto ) This Horizons Infosheet contains information on venetoclax, a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides information relating to
More informationThe role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)
in partnership with The role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) CTRad Clinical Trials Workshop 14/10/2014 What is
More informationNCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT)
NCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT) This is a draft document subject to agreement Version Date Amendment Approved By 1 05/04/16 Initial Draft 1 Table of Contents
More informationUK STRATIFIED MEDICINE PROGRAMME: NGS ANALYSIS AND CHALLENGES OF REPORTING. Dr. Alessandro Rettino West Midlands Regional Genetics Laboratory
UK STRATIFIED MEDICINE PROGRAMME: NGS ANALYSIS AND CHALLENGES OF REPORTING Dr. Alessandro Rettino West Midlands Regional Genetics Laboratory Overview CRUK Stratified Medicine Programme phase 1 and 2 CRUK
More informationTRIANGLE TRIAL SYNOPSIS V1.1 (12.MAY2016) Study Overview (Figure 1 and 2)
PAGE 1 OF 12 Title Short title : autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing induction in Generalized mantle cell Lymphoma EudraCT-no. Trial design Randomized, three-arm, parallel-group,
More informationDevelopment and Implications of a Redacted Clinical Trial Protocol for Posting Online With the Published Manuscripts
Development and Implications of a Redacted Clinical Trial Protocol for Posting Online With the Published Manuscripts Namit Ghildyal, Yvette Ng, Craig Tendler, Chris H. Takimoto, Susan Glasser Janssen Research
More informationMultiple Myeloma Update PMMNG 13 Feb Outline. Alfred Garfall MD Edward Stadtmauer MD
Multiple Update PMMNG 13 Feb 2016 Alfred Garfall MD Edward Stadtmauer MD Outline w Updates on existing/approved drugs for multiple myeloma w Updates on new/upcoming drugs and strategies for multiple myeloma
More informationHematopoietic Stem Cell Transplant in Myeloma. Gary Simmons, DO
Hematopoietic Stem Cell Transplant in Myeloma Gary Simmons, DO Objectives What is the benefit of ASCT What is Upfront therapy and with novel agent era- does it include ASCT Is response before and after
More informationPatient samples were provided by the International ML-DS Study Group.
Patient samples were provided by the International ML-DS Study Group. Samples provided to the Weatherall Institute of Molecular Medicine, Oxford by: D. Webb, P. Ancliff, Department of Haematology and Oncology,
More informationAccuracy of bacterial DNA testing for central venous catheter-associated bloodstream infection in children with cancer
Accuracy of bacterial DNA testing for CVC-associated BSI in children with cancer Accuracy of bacterial DNA testing for central venous catheter-associated bloodstream infection in children with cancer M
More informationClinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationScottish Medicines Consortium
Scottish Medicines Consortium interferon alfa 2b (Viraferon and Intron A* ) 18 million IU, solution for injection, multidose pen in combination with ribavirin (Rebetol ) capsules 200 mg No. (258/06) Schering
More informationCell and Gene Therapy Catapult preclinical database
Cell and Gene Therapy Catapult preclinical database The UK Preclinical Database covers preclinical research activity concerning cell, gene and other advanced therapies that the Cell and Gene Therapy Catapult
More informationNCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT) Version Date Amendment Approved By 1 03/06/16 Version 1 Working Group
NCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT) Version Date Amendment Approved By 1 03/06/16 Version 1 Working Group 1 Table of Contents Acknowledgements... 3 1 Background...
More informationNumber Of Applications. Number Funded
RESEARCH ORGANISATION DEPARTMENTAL SUCCESS RATES 2012/13 This data is associated with proposals submitted to NERC Responsive, Research Programme and Knowledge Exchange schemes. Research Fellowships and
More informationWhat s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials
Vol. 14, No. 10, October 2018 Happy Trials to You What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials While multiple, concurrently accruing patient cohorts in first-in-human (FIH)
More informationThe use of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer
TECHNOLOGY ASSESSMENT REPORTS FOR THE HTA PROGRAMME The use of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer A. Final version. B. Details of review team ScHARR Assessment Team
More informationA biomarker-based adaptive two-stage randomizedphase II study design
A biomarker-based adaptive two-stage randomizedphase II study design Virginia L. Filiaci, PhD Mark F. Brady, PhD Gynecologic Oncology Group Statistical and Data Center Trial Design Setting Phase II Putative
More informationTherapeutic Apheresis Services. Annual Review 2015/16
Therapeutic Apheresis Services Annual Review 2015/16 1 OVERVIEW NHS Blood and Transplant (NHSBT) is a major provider of Therapeutic Apheresis Services (TAS) in the NHS. At the end of each financial year,
More informationPublished 13 June 2011 Page May 2011
filgrastim, 30 million units (300 micrograms)/0.5ml, 48 million units (480 micrograms)/0.5ml, solution for injection or infusion in pre-filled syringe (Zarzio ) SMC No. (704/11) Sandoz Ltd 06 May 2011
More informationMIDOSTAURIN WITH STANDARD CHEMOTHERAPY IN FLT3 POSITIVE ACUTE MYELOID LEUKAEMIA. Project ID: PTJA01. Project description and planning
MIDOSTAURIN WITH STANDARD CHEMOTHERAPY IN FLT3 POSITIVE ACUTE MYELOID LEUKAEMIA Project ID: PTJA01 Project description and planning Authors: Finnish Medicines Agency Co-authors: rwegian Medicines Agency
More informationClinical Policy: Thalidomide (Thalomid) Reference Number: ERX.SPMN.95
Clinical Policy: (Thalomid) Reference Number: ERX.SPMN.95 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationBUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY. Myeloma Canada s experience
BUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY Myeloma Canada s experience WHO WE ARE Myeloma Canada is a registered non-profit organization created by, and for people living with multiple
More informationBIOMEDICAL RESEARCH CENTRES
Introduction BIOMEDICAL RESEARCH CENTRES The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the
More informationModule Guide 2016/17: Statistics for the Oncologist
MSc Oncology Including PG Certificate and PG Diploma Part A: Basic Sciences Module Guide 2016/17: Statistics for the Oncologist Contents 1. Module Details 3 2. Joint Module Leaders and Course Administration
More informationGemzar (gemcitabine) is currently approved in adult patients for use in the treatment of:
INTRODUCTION Hospira, Inc. submitted a 505(b)(2) NDA (200-795) for Gemcitabine Injection on December 11, 2009. The Reference Listed Drug (RLD) is Gemzar (gemcitabine hydrochloride) Injection, Powder, Lyophilized,
More informationLast Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4
STANDARD OPERATING PROCEDURE (SOP) FOR CLINICAL RESEARCH Title: Investigational Drug Billing Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4 1. PURPOSE: To assure accurate and
More informationROOTMETRICS NETWORK PERFORMANCE RESULTS H2, 2013
ROOTMETRICS NETWORK PERFORMANCE RESULTS H, 0 Big news. THE LATEST ROOTMETRICS TEST RESULTS SHOW THAT OUR NETWORK IS THE UK S BIGGEST, FASTEST AND MOST RELIABLE. It s official. Hang out the bunting. Contents
More informationConceptual Framework for the Integration of Wastewater and Hospital Emergencies Data
Conceptual Framework for the Integration of Wastewater and Hospital Emergencies Data Dr David M Wood 1, Dr Kevin V Thomas 2, Prof Paul I Dargan 1 1 Guy s and St Thomas NHS Foundation Trust, King s Health
More informationhealthcare built better by western
healthcare built better by western WESTERN PROVIDE BESPOKE BUILD SOLUTIONS TO THE HEALTH SECTOR WITH HEALTH AUTHORITIES AND TRUSTS HAVING TO OPERATE IN AN ENVIRONMENT CHARACTERISED BY PRESSURE ON BOTH
More informationJoint Research Office of Doncaster & Bassetlaw
Page 1 of 11 Hospitals NHS, Rotherham Doncaster & South Humber NHS and NHS Signatures: Role Name Function Date (DD-MM-YYYY) Signature Author Amy Beckitt Clinical Research Development Manager Reviewer Dr
More informationA prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase
Supplemental file accompanying the paper: A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia Wing H.
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for Multiple Myeloma July 31, 2014
pan-canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for Multiple Myeloma July 31, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationNIHR TRANSLATIONAL RESEARCH COLLABORATION INFLAMMATORY RESPIRATORY DISEASE
NIHR TRANSLATIONAL RESEARCH COLLABORATION INFLAMMATORY RESPIRATORY DISEASE EXPERTISE AND CAPABILITIES The TRC in Inflammatory Respiratory Disease provides cutting-edge expertise in the development of exploratory
More information63, ,927 sq ft. Be operational Q THREE NEW UNITS FROM IMPERIALPARK.CO.UK SAT NAV: CV3 4PB COVENTRY A45 M6 M40 M42 M1
COVENTRY A45 M6 M40 M42 M1 THREE NEW UNITS FROM 63,344 346,927 sq ft Be operational Q2 2017 COVENTRY A45 M6 M40 M42 M1 IMPERIALPARK.CO.UK SAT NAV: CV3 4PB MULTIPLE CHOICE THREE NEW UNITS FROM 63,344 346,927
More informationDaratumumab (Darzalex )
Daratumumab (Darzalex ) This Horizons Infosheet contains information on daratumumab (also known as Darzalex), a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides
More informationPROTECTIVE MARKING: NONE NHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 15 August 2017 at 14:30 in the Board Room, Aberdeen Royal Infirmary
NHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 15 August 2017 at 14:30 in the Board Room, Aberdeen Royal Infirmary PRESENT APOLOGIES APPROVED Dr D Culligan Dr D Counter Ms A Davie Dr J Fitton Ms
More informationPREPARING TO RUN A TRIAL
PREPARING TO RUN A TRIAL PHASE 1 STUDIES This phase is designed to assess the safety (pharmacovigilance), tolerability, pharmacokinetics, and pharmacodynamics of a drug. STUDY DESIGN Phase I clinical trials
More informationMyeloid growth factors
Are all GFs equal? How say I? G CSF Filgrastim (Neupogen) G CSF Lenograstim (Granocyte) G CSF Pegfilgrastim (Neulasta, / Neulastim) GM CSF (Molgramostim) GM CSF Sargramostim (Leukine) Myeloid growth
More informationCardiff and Vale University Health Board. Rachel Pressley, Senior HR Policy & Compliance Officer Rebecca Marsh, Assistant HR Manager
Section A: Assessment Cardiff and Vale University Health Board Name of Policy Person/persons conducting this assessment with Contact Details RECRUITMENT AND SELECTION POLICY Rachel Pressley, Senior HR
More informationValue Assessment: Building Payercentric value propositions to inform decision-making
Value Assessment: Building Payercentric value propositions to inform decision-making Aris Angelis and Panos Kanavos Medical Technology Research Group, LSE Health Advance-HTA dissemination workshop, Santiago,
More informationTrust Board Meeting: Wednesday 8 July 2015 TB
Trust Board Meeting: Wednesday 8 July 2015 Title NIHR Reporting of R&D Metrics Status History A paper for information The Trust Management Executive received an update on the performance of the Trust with
More informationDrug Name (select from list of drugs shown) Tysabri (natalizumab) Quantity Frequency Strength Route of Administration
04/30/2014 Prior Authorization Form MERCY CARE PLAN (MEDICAID) Tysabri (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lumoxiti) Reference Number: CP.PHAR.398 Effective Date: 10.16.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationTechnology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta457
Carfilzomib for previously treated multiple myeloma Technology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta457 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationFunding for diagnostic test development and opportunities to collaborate with academia.
Funding for diagnostic test development and opportunities to collaborate with academia. Mr Ravi Chana NIHR Office for Clinical Research Infrastructure (NOCRI) Overview RESEARCH FUNDING NIHR INFRASTRUCTURE
More informationVaccine Clinical. Cancer. Group. Trial. Working. Workstream 2. Design Methodologies in Cancer Vaccine Clinical Trials
Cancer Vaccine Clinical Trial Working Group Workstream 2 Design Methodologies in Cancer Vaccine Clinical Trials Workstream 2 - Participants Chris Beattie Onyvax Axel Hoos BMS Vance Berger NCI Michael Kalos
More informationClinical trials for brain tumours
Clinical trials for brain tumours The purpose of clinical trials for brain tumour patients is to gain a better understanding of these tumours and improve diagnosis and treatment. Some trials also seek
More informationBeta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32)
Public slides part 1 (Redacted) Beta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32) 3 rd Appraisal Committee meeting Committee B, 16 th November 2017 Previous Appraisal
More informationDisclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018
Disclosure Hemophilia: The Royal Treatment Nikki Heeren, PharmD PGY1 Resident Avera McKennan Hospital I have had no financial relationship over the past 12 months with any commercial sponsor with a vested
More informationJune 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB
June 15, 2016 Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA five consecutive audits
More informationThe rheumatoid arthritis drug development model: a case study in Bayesian clinical trial simulation
The rheumatoid arthritis drug development model: a case study in Bayesian clinical trial simulation Richard Nixon, Modeling and Simulation, Novartis PSI journal club, 2010 March 24 1 Bayesian clinical
More informationDirect anticoagulation therapy
Direct anticoagulation therapy Pan-Arab Meeting & Saudi Society of Hematology Dr Ihab Alhemaidi MBBS MRCP(Lond UK) FRCPath. Fellow of the Royal Society of Medicine Consultant Adult hematology/bmt Section
More informationlab furniture + fume cupboards Ecoline 2 The high safety low energy fume cupboard
lab furniture + fume cupboards Ecoline 2 The high safety low energy fume cupboard Creating Safe and Environmentally Friendly Working Environments Ecoline 2 is a range of walk-in and drive-in fume cupboards
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationGenomics and personalised medicine
Genomics and personalised medicine Dr Tom Fowler, Deputy Chief Scientist & Director of Public Health WHO Symposium on the Future of Digital Health Systems in the European Region February 2019 About me
More informationExpectations 2011/12. Higher. Benchmarking and competitor analysis for higher education institutions Custom reports & data
Benchmarking and competitor analysis for higher education institutions Custom reports & data NEW discount packages Free presentations Free sample boosting Higher Expectations 2011/12 in association with
More informationThe Future of Apprenticeships in England
The Future of Apprenticeships in England Apprenticeship Standard for Assistant Business Administrator at Level 2 Final Report Executive Summary Health Education England (HEE) commissioned Skills for Health
More informationComparison of admission rates to neonatal units between PO screening and non-po screening Units
London - Westminster Research Ethics Committee 4 Minshull Street Manchester M1 3DZ Telephone: 0207 104 8012 Please note: This is the favourable opinion of the REC only and does not allow you to start your
More informationMaking the case for a place based systems approach to healthy and sustainable food
Making the case for a place based systems approach to healthy and sustainable food Public Health professionals assessment of Sustainable Food Cities Existing evidence indicates that making healthier foods
More informationpan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation
pan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation Ixazomib (Ninlaro) for Multiple Myeloma Myeloma Canada June 29, 2017 1. Feedback
More informationReport of National Plasma Product Expert Advisory Group (NPPEAG) For Approval by the NHS Board Chief Executives Group
Report of National Plasma Product Expert Advisory Group (NPPEAG) 2015 For Approval by the NHS Board Chief Executives Group Table of Contents Purpose... 1 Summary... 1 Background to Plasma Products... 1
More informationAdaptive design development and implementation: practical experiences from the trial
Adaptive design development and implementation: practical experiences from the trial Christopher Weir Pamela Warner Christian Holm Hansen Hilary Critchley Adaptive Designs Workshop 27-28 January 2014,
More information9/7/17. Implementing the ARK Immunoassay for Therapeutic Drug Monitoring of High-Dose Methotrexate. Disclosure. Learning Objectives
Implementing the ARK Immunoassay for Therapeutic Drug Monitoring of High-Dose Methotrexate Kristine R. Crews, PharmD, FCCP, BCPS St. Jude Children s Research Hospital September 14, 2017 Disclosure I declare
More informationCladribine. Spirella Building, Letchworth, SG6 4ET reg charity no
Cladribine Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Cladribine Date of issue: February 2009 Contents Section Page 1. Introduction 1 2. How cladribine
More informationSustainable Food Cities approach
Sustainable Food Cities approach Creating a city-wide cross-sector partnership of public agencies (health, environment, economy), businesses, NGOs, community organisations and academic bodies. Developing
More informationKey elements in a successful MedTech translational research and development proposal
Key elements in a successful MedTech translational research and development proposal Dr. Peter Jarritt Ph.D. FIPEM. (Hon)FRCP. Deputy Director NIHR Healthcare Technology Cooperative Brain Injury Cambridge
More information